Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

BACKGROUND: Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical trial. The purpose of this study was to evaluate the median ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörner, Thomas, van Vollenhoven, Ronald F., Doria, Andrea, Jia, Bochao, Ross Terres, Jorge A., Silk, Maria E., de Bono, Stephanie, Fischer, Peter, Wallace, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109322/
https://www.ncbi.nlm.nih.gov/pubmed/35578304
http://dx.doi.org/10.1186/s13075-022-02794-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109322/
https://www.ncbi.nlm.nih.gov/pubmed/35578304
http://dx.doi.org/10.1186/s13075-022-02794-x

Ejemplares similares